Tuesday, February 23, 2010
Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
IN VIVO: The Business & Medicine Report
Pages
Follow Us ...
| ||||||||
Headlines from 'The Pink Sheet' DAILY
Contributors
Labels
About This Blog
Welcome to The IN VIVO Blog, home of daily commentary on recent developments in biopharmaceutical business development, R&D, financing, marketing, and policy. Join us for discussion in the comments, or contact us via email.
Click These Links!
Blog Archive
-
▼
2010
(261)
-
▼
February
(26)
- Deals of the Week is Not Optional
- Financings of the Fortnight Needs a Haircut
- Another Snowstorm, Another Complete Response Letter?
- Merck Puts Up Its Asset-Sale Shingle
- Washing Away Post-Deal Blues With A De-Sanofizer
- What's on Steve Nissen's Tape Recorder?
- While You Were Upsetting
- Deals of the Week Has Gold Medals and Free Money o...
- Swiss Addex Now on BVF's Watch List
- XenoPort Experiences Restless Investor Syndrome
- While You Were Watching Winter Sports ...
- NICE Snubs Novo With Draft Lira Guidance
- PhRMA Changes Leaders: A Dozen Candidates We Bet W...
- PhRMA Changing Leaders; Will It Change Tack in Hea...
- DotW: Shovel Ready
- Tauzin Stepping Down at PhRMA
- Financings of the Fortnight's Symphonic Overtones
- Vernalis Buys Back Migraine Drug's EU Royalties
- Crucell: Revving the R&D Engine
- Health Care Reform: Digging Out From “Paralyzing S...
- "No!" says NICE, to Sprycel, Tasigna
- What's in Your Pipeline? The Feds Want to Know
- "Can we Learn to Love Diagnostics?" asks Roche's N...
- While You Were: Snowpocalypse Now
- DotW: IPO Medicine
- Europe Matters, says Cephalon, with $590m Mepha Deal
-
▼
February
(26)
Footer
IN VIVO: The Business & Medicine Report
© Copyright 2014 Informa plc.
Informa Business Information. All Rights Reserved.
www.pharmamedtechbi.com
1 comment:
That is simply hilarious.
Post a Comment